The C21orf2 gene plays a significant role in the health and functionality of the retina, particularly influencing the development of cone-rod dystrophy, a genetic disorder that affects the eyes. Cone-rod dystrophy is characterized by the progressive loss of vision, starting with the deterioration of cone cells (responsible for color vision and visual acuity) and followed by rod cells (which enable low-light vision). Mutations in the C21orf2 gene have been identified as a causative factor for this condition, making genetic testing a valuable tool for diagnosis and understanding the risk of inheritance.
DNA Labs UAE offers a specialized genetic test aimed at detecting mutations in the C21orf2 gene, providing essential information for individuals with a family history of cone-rod dystrophy or those experiencing symptoms related to the disorder. The test is a critical step in the diagnosis process, offering insights that can guide treatment and management decisions, as well as inform family planning considerations.
The cost of the C21orf2 gene-related cone-rod dystrophy genetic test at DNA Labs UAE is 4400 AED. This investment covers the collection of a DNA sample, usually through a blood draw or cheek swab, and its subsequent analysis in the laboratory. The process is designed to be as non-invasive and straightforward as possible, with results typically available within a few weeks. The outcome of the test can provide individuals and their healthcare providers with crucial information to better understand the condition, its progression, and potential interventions to manage symptoms and improve quality of life.
The GCNT2 gene cataract autosomal dominant genetic test is a specialized diagnostic tool designed to identify mutations in the GCNT2 gene, which are associated with a form of cataract inherited in an autosomal dominant manner. Cataracts, characterized by the clouding of the eye's lens, can lead to diminished vision and, if untreated, blindness. The specific mutations in the GCNT2 gene linked to this condition can result in an early onset of cataract development, distinguishing it from age-related cataracts.
This genetic test is crucial for families with a history of early cataract development, as it helps in the early detection and management of the condition. Early diagnosis can lead to timely interventions, potentially preserving vision and improving the quality of life for affected individuals. Moreover, understanding the genetic basis of the condition can provide valuable information for family planning and genetic counseling.
The test is available at DNA Labs UAE, a leading facility in genetic diagnostics, offering a comprehensive range of genetic testing services. The cost of the GCNT2 gene cataract autosomal dominant genetic test is 4400 AED. This price reflects the intricate processes involved in genetic analysis, including DNA extraction, amplification, and sequencing, which are necessary to accurately identify mutations in the GCNT2 gene.
By opting for this test at DNA Labs UAE, individuals and families gain access to state-of-the-art genetic testing technologies, expert interpretation of results, and personalized advice on managing and mitigating the risks associated with hereditary cataracts.
The "CRYBB3 Gene Cataract Autosomal Recessive Congenital Nuclear Type 2 Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the CRYBB3 gene that are associated with the development of a specific type of cataract. This condition, known as autosomal recessive congenital nuclear cataract type 2, is characterized by the clouding of the eye's lens at birth or shortly thereafter, affecting vision. The test is critical for early diagnosis and management of the condition, facilitating personalized treatment plans and potentially preventing severe vision impairment.
The genetic test involves analyzing the patient's DNA to identify mutations in the CRYBB3 gene, which plays a crucial role in the development and maintenance of lens transparency in the eye. Identifying mutations in this gene can confirm the diagnosis and help in understanding the inheritance pattern within a family, offering insights into the risk for future offspring.
The cost of the test is set at 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results. Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities, this test represents a significant step forward in the early detection and management of congenital cataract conditions, offering hope and improved outcomes for affected individuals and their families.
The "CRYAA Gene Cataract Autosomal Recessive Congenital Type 1 Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE. This test specifically targets the CRYAA gene, which plays a crucial role in the development of the eye's lens. Mutations in the CRYAA gene can lead to autosomal recessive congenital cataracts, a condition characterized by clouding of the lens at birth or shortly thereafter, potentially resulting in significant visual impairment or blindness if not diagnosed and treated promptly.
The genetic test is designed to detect mutations within the CRYAA gene, providing essential information for accurate diagnosis and guiding treatment decisions. By identifying the genetic underpinnings of the condition, the test can also offer valuable insights into the risk of recurrence in future pregnancies, assisting families in making informed reproductive choices.
Priced at 4400 AED, the test is conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services. The cost reflects the sophisticated technology and expertise required to accurately identify mutations in the CRYAA gene. This test is a vital resource for families affected by congenital cataracts, offering hope for early intervention and the potential for better visual outcomes.
The "FYCO1 Gene Cataract Autosomal Recessive Congenital Type 2 Genetic Test" is a specialized diagnostic examination designed to detect mutations in the FYCO1 gene, which are linked to the development of Autosomal Recessive Congenital Cataracts Type 2 (ARCC2). This condition is a rare, hereditary eye disorder that manifests from birth or early childhood, leading to clouding of the lens in the eye and potentially severe visual impairment or blindness if not diagnosed and managed appropriately.
The test is crucial for families with a history of this condition, as it aids in early detection, allowing for timely intervention and management strategies to preserve vision. It involves analyzing the patient's DNA to identify mutations in the FYCO1 gene, which plays a significant role in lens development and clarity. By pinpointing these genetic alterations, healthcare providers can confirm a diagnosis of ARCC2, guide treatment decisions, and offer genetic counseling to affected families.
Offered by DNA Labs UAE, the test cost is 4400 AED. DNA Labs UAE is equipped with advanced genetic testing facilities and expertise, ensuring high accuracy and reliability of the test results. This test is an important tool in the field of genetic ophthalmology, offering hope and crucial information for individuals and families grappling with the challenges of congenital cataracts.
The "SORD Gene Cataract Congenital Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying congenital cataracts linked to mutations in the SORD gene. Congenital cataracts, which can appear in newborns or develop in early childhood, are primarily characterized by the clouding of the eye's lens, potentially leading to vision impairment or blindness if not timely addressed. The SORD gene, implicated in various metabolic pathways, has been associated with this specific type of cataract, making its examination crucial for early detection and management.
DNA Labs UAE offers this cutting-edge genetic test for a cost of 4400 AED. The test is designed to provide precise and reliable results, enabling healthcare providers to develop personalized treatment plans for affected individuals. By identifying the genetic mutation early, interventions can be more effectively tailored to prevent the progression of vision loss and improve the quality of life for those diagnosed with this condition. This test is an essential tool in the arsenal against congenital cataracts, offering hope and solutions to families dealing with this challenging diagnosis.
The SIL1 gene plays a crucial role in the development and maintenance of clear lenses in the eyes and proper muscle function. Mutations in the SIL1 gene are closely associated with a rare genetic disorder known as Marinesco-Sjögren Syndrome (MSS), which is characterized by congenital cataracts, progressive muscle weakness, cerebellar ataxia, and developmental delays. Identifying mutations in the SIL1 gene is crucial for the diagnosis and understanding of the syndrome, allowing for better management and care of affected individuals.
DNA Labs UAE offers a genetic test specifically designed to detect mutations in the SIL1 gene, providing a valuable tool for diagnosing Marinesco-Sjögren Syndrome and associated congenital cataracts. This test is particularly important for individuals showing symptoms of MSS or those with a family history of the syndrome. Early detection through genetic testing can facilitate timely intervention and support, potentially improving the quality of life for those affected.
The cost of the SIL1 gene cataract congenital associated with Marinesco-Sjögren Syndrome genetic test at DNA Labs UAE is 4400 AED. The test involves a simple sample collection process, after which the sample is analyzed for specific genetic mutations in the SIL1 gene. Results from the test can provide crucial information for families and healthcare providers, guiding further medical and supportive care decisions for individuals with MSS.
The "LIM2 Gene Cataract Cortical Pulverulent Late-Onset Genetic Test" is a specialized diagnostic examination designed to identify mutations in the LIM2 gene, which are associated with the development of late-onset cortical pulverulent cataracts. Cataracts are characterized by the clouding of the lens in the eye, leading to decreased vision, and the LIM2 gene plays a crucial role in maintaining lens transparency. Mutations in this gene can disrupt lens fiber cell membrane integrity, leading to the formation of cataracts.
This genetic test is particularly valuable for individuals who have a family history of cataracts or have been identified as having symptoms suggestive of this specific type of cataract. Early identification of mutations can aid in the management and treatment planning for affected individuals, potentially leading to better outcomes.
The test is conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The cost of the test is set at 4400 AED. It involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the LIM2 gene. Results from this test can provide crucial information for patients and their families regarding the risk of developing late-onset cortical pulverulent cataracts and can guide decisions about monitoring and intervention strategies.
The HSF4 Gene Cataract Lamellar Genetic Test is a specialized diagnostic procedure designed to identify mutations in the HSF4 gene, which are known to cause lamellar cataracts. Lamellar cataracts are a specific type of cataract characterized by a layered, opacification of the lens, which can lead to impaired vision. This genetic testing is crucial for early detection and management of the condition, potentially preventing severe vision loss.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, this test offers a comprehensive analysis of the HSF4 gene to determine an individual's risk of developing lamellar cataracts. The process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the lab for any genetic abnormalities associated with the condition.
The cost of the HSF4 Gene Cataract Lamellar Genetic Test is 4400 AED. This investment covers the full process of genetic screening, from sample collection to detailed reporting of results. Given the specialized nature of this test and its potential to significantly impact the management and treatment of lamellar cataracts, it represents a valuable tool for individuals with a family history of the condition or those experiencing symptoms suggestive of cataracts.
The "CRYAB Gene Cataract Posterior Polar Type 2 Genetic Test" is a specialized diagnostic tool used to identify mutations in the CRYAB gene, which are associated with the development of Cataract Posterior Polar Type 2, a specific type of cataract characterized by a distinctive opacity at the back of the lens of the eye. This condition can lead to a decrease in visual clarity and, if left undiagnosed, can progress to more severe vision impairment or blindness. The test is particularly valuable for individuals who have a family history of this condition or exhibit symptoms suggestive of posterior polar cataracts, as early detection can facilitate timely management and treatment strategies.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed to detect any abnormalities or mutations in the CRYAB gene. These mutations are known to disrupt the normal function of alpha-crystallin B, a protein crucial for maintaining the transparency and refractive index of the lens, thereby leading to the development of cataracts.
The cost of the "CRYAB Gene Cataract Posterior Polar Type 2 Genetic Test" at DNA Labs UAE is set at 4400 AED. While the price may seem significant, the value of the test lies in its ability to provide crucial genetic information that can guide clinical decisions, inform treatment options, and potentially prevent the progression of the disease. For families affected by this condition, the test also offers the possibility of genetic counseling and understanding the risk of transmission to future generations.
